Renaissance Technologies LLC Acquires New Shares in NeoGenomics, Inc. $NEO

Posted by Stanley Muller on Aug 12th, 2026

Renaissance Technologies LLC purchased a new stake in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 254,172 shares of the medical research company’s stock, valued at approximately $1,886,000. Renaissance Technologies LLC owned approximately 0.20% of NeoGenomics at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Sei Investments Co. grew its holdings in NeoGenomics by 320.7% during the 1st quarter. Sei Investments Co. now owns 466,199 shares of the medical research company’s stock valued at $3,459,000 after buying an additional 355,379 shares during the last quarter. Granite Investment Partners LLC acquired a new position in shares of NeoGenomics in the first quarter worth $5,583,000. Dimensional Fund Advisors LP raised its holdings in shares of NeoGenomics by 9.2% in the first quarter. Dimensional Fund Advisors LP now owns 2,674,335 shares of the medical research company’s stock worth $19,842,000 after acquiring an additional 225,588 shares during the last quarter. Gamco Investors INC. ET AL lifted its position in shares of NeoGenomics by 525.0% in the first quarter. Gamco Investors INC. ET AL now owns 100,000 shares of the medical research company’s stock valued at $742,000 after acquiring an additional 84,000 shares in the last quarter. Finally, First Trust Advisors LP purchased a new stake in shares of NeoGenomics in the first quarter valued at $45,725,000. 98.50% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other NeoGenomics news, Director Lynn A. Tetrault sold 5,307 shares of the business’s stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $11.29, for a total transaction of $59,916.03. Following the completion of the sale, the director owned 91,422 shares of the company’s stock, valued at approximately $1,032,154.38. The trade was a 5.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.10% of the company’s stock.

NeoGenomics Price Performance

NEO opened at $16.53 on Wednesday. NeoGenomics, Inc. has a 1 year low of $5.78 and a 1 year high of $16.92. The company’s 50 day simple moving average is $13.65 and its 200 day simple moving average is $10.87. The stock has a market capitalization of $2.12 billion, a PE ratio of -41.33 and a beta of 1.74. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.35 and a current ratio of 3.60.

NeoGenomics (NASDAQ:NEO – Get Free Report) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.02. The company had revenue of $201.66 million for the quarter, compared to the consensus estimate of $196.93 million. NeoGenomics had a negative net margin of 6.77% and a negative return on equity of 1.99%. NeoGenomics’s revenue was up 11.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.03 earnings per share. As a group, sell-side analysts expect that NeoGenomics, Inc. will post -0.09 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently commented on the company. Zacks Research upgraded NeoGenomics from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 31st. Benchmark upped their target price on shares of NeoGenomics from $11.00 to $16.00 and gave the company a “buy” rating in a report on Friday, July 24th. TD Cowen reaffirmed a “buy” rating on shares of NeoGenomics in a research note on Wednesday, July 15th. Needham & Company LLC lifted their price target on shares of NeoGenomics from $15.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Finally, Weiss Ratings upgraded shares of NeoGenomics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $16.71.

View Our Latest Stock Analysis on NEO

NeoGenomics Company Profile

(Free Report)

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.